Figures & data
Table I. Results of randomized phase III studies of gemcitabine combinations in advanced pancreatic cancer.
Table II. Results of randomized phase III studies of gemcitabine + targeted agents in advanced pancreatic cancer.
Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94(4)902–10 Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. (Abstract 1003). Proc Am Soc Clin Oncol 2003; 22: 250 Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20(15)3270–5 Riess, H, Helm, A, Niedergethmann, M, Schmidt-Wolf, I, Moik, M, Hammer, C, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. Gemcitabine alone in patients with advanced pancreatic cancer. Proc Soc Am Clin Oncol 2005, (abstract 4009). Louvet C, Labianca R, Hammel P, Lledo G, De Baud F, Andre T, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR /GISCAD Intergroup Phase III. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting edition) 2004; 22(14S)4008 Rocha Lima CM, Green MR, Rotche R, Miller WJ, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22(18)3776–83 Richards DA, Kindler HL, Oettle H, Ramanthan R, Van Laethem J-L, Peeters M, et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22(14S)4007 O Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano MR, Hurwitz H, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22(14S)4006 Herrmann, R, Bodoky, G, Ruhstaller, T, Glimelius, B, Saletti, P, Bajetta, E, et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc Am Soc Clin Oncol 2005, (abstract 4010). Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6(6)369–76 Stathopoulos, G, Aravantinos, G, Syrigos, K, Kalbakis, K, Karvounis, N, Papakotoulas, P, et al. A randomized phase III study of Irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005, (abstract 4106). Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87(2)161–7 Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22(8)1430–8 Moore, MJ, Goldstein, D, Hamm, J, Kotecha, J, Gallinger, S, Au, HJ, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005, Gastrointestinal Cancers Symposium (abstract 77). Shapiro, J, Marshall, J, Karasek, P, Figer, A, Oettle, H, Couture, F, et al. G17DT + gemcitabine [Gem] versus placebo + Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. Proc Am Soc Clin Oncol 2005, (abstract 4012).